Published in Neurology on July 23, 2002
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17
Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann N Y Acad Sci (2008) 1.85
Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord (2015) 1.52
Warfarin reversal. J Clin Pathol (2004) 1.33
Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes (2009) 1.29
Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol (2012) 1.14
Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis (2008) 1.07
New oral anticoagulants may be particularly useful for asian stroke patients. J Stroke (2014) 1.00
Mixed cerebrovascular disease and the future of stroke prevention. Transl Stroke Res (2012) 0.97
Risk of intraparenchymal hemorrhage with magnetic resonance imaging-defined leukoaraiosis and brain infarcts. Ann Neurol (2012) 0.94
Relationship between white-matter hyperintensities and hematoma volume and growth in patients with intracerebral hemorrhage. Stroke (2009) 0.93
Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol (2011) 0.85
Warfarin-induced intracerebral hemorrhage associated with microbleeds. J Clin Neurol (2008) 0.82
MRI screening for chronic anticoagulation in atrial fibrillation. Front Neurol (2013) 0.82
Brain regulation of thrombosis and hemostasis: from theory to practice. Stroke (2013) 0.80
Binswanger's disease: toward a diagnosis agreement and therapeutic approach. Expert Rev Neurother (2014) 0.78
Leukoaraiosis on magnetic resonance imaging is related to long-term poor functional outcome after thrombolysis in acute ischemic stroke. J Korean Neurosurg Soc (2011) 0.78
Need for Continued Use of Anticoagulants After Intracerebral Hemorrhage. Curr Treat Options Cardiovasc Med (2003) 0.77
Oral anticoagulant-associated intracerebral hemorrhage. J Neurol (2011) 0.77
Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies? Curr Cardiol Rep (2013) 0.77
Management of anticoagulant-related intracranial hemorrhage: an evidence-based review. Crit Care (2014) 0.76
Increased Risk of Post-Thrombolysis Intracranial Hemorrhage in Acute Ischemic Stroke Patients with Leukoaraiosis: A Meta-Analysis. PLoS One (2016) 0.76
Testing for CYP2C9 before initiating anticoagulant therapy. J Gen Intern Med (2009) 0.75
Making anticoagulation safer. Neurology (2002) 0.75
Clinical neurogenetics: stroke. Neurol Clin (2013) 0.75
Resumption of Anticoagulation After Intracranial Hemorrhage. Curr Treat Options Neurol (2017) 0.75
Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology (2001) 6.42
Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med (1999) 4.54
Distribution of the cell substratum attachment (CSAT) antigen on myogenic and fibroblastic cells in culture. J Cell Biol (1985) 3.76
Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology (2006) 3.68
Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol (2001) 3.46
Developmental defects in mouse embryos lacking N-cadherin. Dev Biol (1997) 3.39
Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology (2007) 3.38
Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology (2010) 3.31
Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med (2000) 3.23
Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology (2004) 2.85
The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med (1995) 2.68
Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology (2000) 2.59
White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology (2010) 2.49
Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology (2009) 2.47
MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol (2008) 2.40
Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology (2010) 2.39
Course of cerebral amyloid angiopathy-related inflammation. Neurology (2007) 2.33
Comparing proxy and patients' perceptions of patients' functional status: results from an outpatient geriatric clinic. J Am Geriatr Soc (1992) 2.16
Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation (2000) 2.09
Membrane glycoproteins involved in cell--substratum adhesion. Proc Natl Acad Sci U S A (1981) 2.08
White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology (2004) 2.07
Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology (2006) 2.06
Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost (2008) 2.05
Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology (2010) 2.02
A monoclonal antibody identifies a glycoprotein complex involved in cell-substratum adhesion. Exp Cell Res (1985) 1.95
Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology (2002) 1.92
Integrin and cadherin synergy regulates contact inhibition of migration and motile activity. J Cell Biol (1998) 1.91
A score to predict early risk of recurrence after ischemic stroke. Neurology (2009) 1.88
Antiplatelet use after intracerebral hemorrhage. Neurology (2006) 1.88
Characterization of the interactions of alpha-catenin with alpha-actinin and beta-catenin/plakoglobin. J Cell Sci (1997) 1.82
Pathogenic effects of D23N Iowa mutant amyloid beta -protein. J Biol Chem (2001) 1.74
P- and E-cadherin are in separate complexes in cells expressing both cadherins. Exp Cell Res (1993) 1.72
Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J Thromb Haemost (2009) 1.68
Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost (2010) 1.68
Yeast mitochondria contain ATP-sensitive, reversible actin-binding activity. Mol Biol Cell (1994) 1.65
Proteins transferred to nitrocellulose for use as immunogens. Anal Biochem (1985) 1.63
Severity of leukoaraiosis correlates with clinical outcome after ischemic stroke. Neurology (2009) 1.56
The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol (1995) 1.56
Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol (1997) 1.54
Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology (2011) 1.50
Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol (1998) 1.47
Cadherins promote skeletal muscle differentiation in three-dimensional cultures. J Cell Biol (1997) 1.47
Current pharmacotherapy for Alzheimer's disease. Annu Rev Med (2006) 1.45
Thrombospondin promotes cell-substratum adhesion. Science (1987) 1.44
Correlations between MRI white matter lesion location and executive function and episodic memory. Neurology (2011) 1.43
Impaired visual evoked flow velocity response in cerebral amyloid angiopathy. Neurology (2008) 1.42
Manipulation of cell-cell and cell-substratum interactions in mouse mammary tumor epithelial cells using broad spectrum antisera. J Cell Biol (1981) 1.41
Cadherins and associated proteins. In Vivo (1992) 1.34
Tandem events in myoblast fusion. Dev Biol (1977) 1.33
Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res (1987) 1.32
Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology (2012) 1.30
Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. Mol Cell Biol (1987) 1.29
Expression of E-cadherin and N-cadherin in surface epithelial-stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors. Hum Pathol (1997) 1.28
Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology (2005) 1.26
Molecular mechanisms for memory: second-messenger induced modifications of protein kinases in nerve cells. Annu Rev Neurosci (1987) 1.24
Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol (2001) 1.22
Low cholesterol as a risk factor for primary intracerebral hemorrhage: A case-control study. Neuroepidemiology (1999) 1.22
N-cadherin-associated proteins in chicken muscle. Differentiation (1991) 1.22
Tissue remodeling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells. Am J Physiol (1996) 1.21
The Causative Classification of Stroke system: an international reliability and optimization study. Neurology (2010) 1.19
Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J Biol Chem (1995) 1.18
N-cadherin promotes the commitment and differentiation of skeletal muscle precursor cells. Dev Biol (1997) 1.16
A molecular mechanism for long-term sensitization in Aplysia. Nature (1987) 1.16
Physicians' attitudes and practices regarding treatment of HIV-infected patients. South Med J (1992) 1.13
Integral membrane glycoproteins related to cell-substratum adhesion in mammalian cells. J Cell Biochem (1982) 1.11
Cadherin junctions in mammary tumors. J Mammary Gland Biol Neoplasia (2001) 1.10
N-cadherin-catenin interaction: necessary component of cardiac cell compartmentalization during early vertebrate heart development. Dev Biol (1997) 1.10
P-cadherin expression in breast carcinoma indicates poor survival. Cancer (1999) 1.09
Clinical characteristics of pathologically proved cholesterol emboli to the brain. Neurology (2000) 1.05
The interaction of thrombospondin with platelet glycoprotein GPIIb-IIIa. J Biol Chem (1989) 1.03
Thrombospondin promotes platelet aggregation. Blood (1988) 1.02
Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology (2011) 1.02
Nuclear localization of E-cadherin expression in Merkel cell carcinoma. Arch Pathol Lab Med (2000) 1.00
The GPIIB-IIIa-like complex may function as a human melanoma cell adhesion receptor for thrombospondin. Exp Cell Res (1989) 0.99
Effects of prolactin upon cholesterol metabolism and progesterone biosynthesis in corpora lutea of rats hyophysectomized during pseudopregnancy. Endocrinology (1970) 0.99
Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease. Hum Mol Genet (1998) 0.99
Differential inhibition of myoblast fusion. Dev Biol (1978) 0.97
N-cadherin/catenin-mediated morphoregulation of somite formation. Dev Biol (1998) 0.96
Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology (2011) 0.96
N-cadherin involvement in cardiac myocyte interaction and myofibrillogenesis. Dev Biol (1994) 0.96